This page contains a Flash digital edition of a book.
What Lies Ahead -


Innovations in IBD Grants Researcher


Institution


Dr. Charles Bernstein


University of Manitoba


Co-investigators: Dr. Laura Targownik University of Manitoba Dr. Hillary Steinhart Mount Sinai Hospital Dr. John Marshall McMaster University


Dr. Stephen Girardin


University of Toronto


Co-investigator: Dr. David Prescott University of Toronto


Dr. Andrew Stadnyk


IWK Health Centre


Co-investigator: Dr. Anthony Otley IWK Health Centre


Dr. Stuart Turvey University of British Columbia


Co-investigators: Dr. Laura Sly


Dr. Hong Yang


University of British Columbia


University of British Columbia


Development of anti-inflammatory nanomedicine for inflammatory bowel disease


$50,000 (1 year)


An innovative approach to cell therapy for Crohn’s disease


$50,000 (1 year)


Targeted genome editing in human intestinal epithelial cells


$50,000 (1 year)


Discovery Grants 2014-2017


In May 2014 our Grant Review Committee met to identify the most promising research to fund in the coming year and we are pleased to announce the additional nine Grant-in-Aid and four Innovations in IBD projects will be funded. These programs support high-quality innovative research projects that will enhance our understanding of Crohn’s disease and ulcerative colitis and have the potential to cure or more effectively control these diseases.


Project


Denosumab (common osteoporosis drug) for the treatment of Crohn’s disease


Investment


$50,000 (1 year)


RESEARCH REPORT 2014 | 22


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32